🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

55,66 USD

Máx. histórico

149,13

4124 días

Caída desde máximo

-62,68%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-3,10%

Cierre anterior

57,44

Rango de hoy

52,00 – 56,32

Volumen hoy

4.698.487

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,33 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 12 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/05/2000 20,94 20,94 18,88 20,25 -7,95% 9,85% 51.700
09/05/2000 20,98 22,06 20,50 22,00 +11,39% 7,45% 66.400
08/05/2000 21,00 21,16 19,75 19,75 -4,82% 6,70% 46.100
05/05/2000 20,25 20,86 20,00 20,75 +3,11% 4,24% 149.600
04/05/2000 21,00 21,00 19,94 20,13 +7,33% 5,06% 51.600
03/05/2000 19,75 20,25 17,94 18,75 -6,54% 11,71% 55.200
02/05/2000 19,50 20,06 19,50 20,06 +5,25% 2,88% 11.100
01/05/2000 19,06 19,06 18,00 19,06 +7,02% 5,57% 28.500
28/04/2000 20,06 20,06 17,81 17,81 -11,21% 11,21% 56.900
27/04/2000 20,38 20,38 20,00 20,06 -3,60% 1,84% 15.100
26/04/2000 19,75 20,81 19,69 20,81 +1,52% 5,70% 9.400
25/04/2000 20,94 21,50 19,63 20,50 -2,38% 8,96% 24.200
24/04/2000 19,75 21,00 19,50 21,00 +3,70% 7,59% 1.000
20/04/2000 19,00 21,50 18,88 20,25 -8,47% 13,82% 24.400
19/04/2000 23,00 23,00 21,94 22,13 -1,67% 4,62% 10.600
18/04/2000 23,00 23,75 21,75 22,50 +6,19% 8,70% 120.400
17/04/2000 20,00 21,25 20,00 21,19 +11,51% 6,25% 58.600
14/04/2000 22,06 22,75 19,00 19,00 -19,15% 17,00% 33.600
13/04/2000 24,19 24,50 23,50 23,50 -1,83% 4,13% 14.500
12/04/2000 23,50 24,50 23,50 23,94 -0,26% 4,26% 33.100
11/04/2000 25,00 25,25 22,88 24,00 -5,88% 9,50% 74.800
10/04/2000 26,38 26,75 25,50 25,50 -5,56% 4,74% 46.400
07/04/2000 27,00 27,38 26,75 27,00 +0,93% 2,31% 46.200
06/04/2000 26,19 27,88 26,19 26,75 +4,90% 6,44% 30.100
05/04/2000 25,69 27,00 25,00 25,50 -5,56% 7,79% 63.900
04/04/2000 27,75 28,00 25,75 27,00 -2,70% 8,11% 21.500
03/04/2000 30,00 30,38 27,75 27,75 -21,83% 8,75% 111.500
31/03/2000 27,00 36,00 26,88 35,50 +30,88% 33,80% 618.100
30/03/2000 27,25 30,38 27,13 27,13 -12,50% 11,93% 220.000
29/03/2000 28,50 32,13 26,75 31,00 +6,44% 18,86% 290.900